To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.
Participants aged 9-45；
Participants aged 18-45 who can provide legal identification，participants aged 9-17 and their guardian can provide legal identification；
Participants and/or their guardian sign an informed consent form;
Axillary temperature less than 37.3 ℃（>14 years old）or less than 37.5℃（≤14 years old）at the time of enrollment；
Have been vaccinated with other HPV vaccines or planned to vaccinate other HPV vaccines during the study period；
Plan to participate other clinical trials during the study period，or participated other clinical trials （including vaccine or drug）and received medication or vaccine within 3 months before enrollment ,
History of positive HPV testing (including types not covered by the trial vaccine) among the participants aged 18-45 years old;
History of CIN2/AIS/Cervical Cancer/Pelvic radiation therapy in female participants;
Shanghai Bovax Biotechnology Co., Ltd.
Lead sponsor